CoChat

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects

Open access
Hausner, Helene, Derving Karsbøl, Julie, Holst, Anders G., Jacobsen, Jacob B., Wagner, Frank-Dietrich, Golor, Georg, Anderson, Thomas W. · 2017 · Clinical Pharmacokinetics

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

BACKGROUND AND OBJECTIVE: Semaglutide is a glucagon-like peptide-1 analogue in development for the once-weekly treatment of type 2 diabetes mellitus. Its effect on the rate and extent of absorption of concomitant oral medications (metformin, warfarin, atorvastatin and digoxin) was evaluated in healthy subjects. METHODS: Subjects received metformin (500 mg twice daily for 3.5 days), warfarin (25 mg, single dose), atorvastatin (40 mg, single dose) or digoxin (0.5 mg, single dose) before and with subcutaneous semaglutide treatment at steady state (1.0 mg). Lack of drug-drug interaction was concluded if the 90% confidence intervals for the area under the plasma concentration-time curve ratio before and with semaglutide were within a pre-specified interval (0.80-1.25). RESULTS: Overall, metformin, warfarin, atorvastatin and digoxin pharmacokinetics were not affected to a clinically relevant degree with semaglutide co-administration. Estimated area under the plasma concentration-time curve ratios for all concomitant medications before and with semaglutide treatment were within the pre-specified interval. In addition, semaglutide did not affect maximum plasma concentration of concomitant medications to a relevant degree. Furthermore, no clinically relevant change in international normalised ratio response to warfarin was observed with semaglutide co-administration. Most adverse events with semaglutide treatment were mild or moderate. Adverse events with semaglutide and co-administered medication were comparable to those reported during treatment with semaglutide alone, and were mostly gastrointestinal related. CONCLUSIONS: No clinically significant pharmacokinetic or pharmacodynamic interactions were identified and no new safety issues observed with combined treatment with semaglutide. This suggests that no dose adjustments should be required when semaglutide is administered concomitantly with these medications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40262-017-0532-6

Cites

Statistics

Figures

Fig. 1 Study design. Atorv atorvastatin, Dig digoxin, Met metformin, Ortho-OH ortho-hydroxylated atorvastatin metabolite, Para-OH para-hydroxylated atorvastatin metabolite, SS steady state, War warfarin. Asterisk Metformin was administered 3.5 days prior to the metformin pharmacokinetic sampling visit. Dagger Administered 48 h after the fifth dose of semaglutide 1.0 mg. Double dagger Administered 48 h after the sixth dose of semaglutide 1.0 mg. Section sign In Study 2, follow-up visit was at visit 12. The subjects received metformin and warfarin in Study 1, and atorvastatin and digoxin in Study 2
Fig. 1 Study design. Atorv atorvastatin, Dig digoxin, Met metformin, Ortho-OH ortho-hydroxylated atorvastatin metabolite, Para-OH para-hydroxylated atorvastatin metabolite, SS steady state, War warfarin. Asterisk Metformin was administered 3.5 days prior to the metformin pharmacokinetic sampling visit. Dagger Administered 48 h after the fifth dose of semaglutide 1.0 mg. Double dagger Administered 48 h after the sixth dose of semaglutide 1.0 mg. Section sign In Study 2, follow-up visit was at visit 12. The subjects received metformin and warfarin in Study 1, and atorvastatin and digoxin in Study 2CC BY-NC · PubMed Central
Fig. 2 Mean pharmacokinetic profiles of metformin (a), S-warfarin* (b), atorvastatin (c) and digoxin (d) before and with semaglutide treatment. Reference line for the lower limit of quantification. Values below the lower limit of quantification are imputed. Asterisk R-warfarin curves are not included here but followed a similar pattern to the S-warfarin curves
Fig. 2 Mean pharmacokinetic profiles of metformin (a), S-warfarin* (b), atorvastatin (c) and digoxin (d) before and with semaglutide treatment. Reference line for the lower limit of quantification. Values below the lower limit of quantification are imputed. Asterisk R-warfarin curves are not included here but followed a similar pattern to the S-warfarin curvesCC BY-NC · PubMed Central
Fig. 3 Estimated exposure ratios for metformin, warfarin, atorvastatin and digoxin before and with semaglutide treatment. Estimated ratios, before vs. with semaglutide treatment and 90% confidence intervals are shown. AUC area under the plasma concentration–time curve, C max maximum plasma concentration (C max limits for atorvastatin and digoxin were not predefined)
Fig. 3 Estimated exposure ratios for metformin, warfarin, atorvastatin and digoxin before and with semaglutide treatment. Estimated ratios, before vs. with semaglutide treatment and 90% confidence intervals are shown. AUC area under the plasma concentration–time curve, C max maximum plasma concentration (C max limits for atorvastatin and digoxin were not predefined)CC BY-NC · PubMed Central
Fig. 4 Mean international normalised ratio (INR) profile for warfarin
Fig. 4 Mean international normalised ratio (INR) profile for warfarinCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 32 · Cited by 62

Research works printed but not linked: 2

  1. Roffel AF, Jensen L, van Lier JJ, et al. Absorption, metabolism and excretion of 3H-semaglutide following a single, subcutaneous dose in healthy male subjects. Diabetologia. 2015;58(suppl 1):S1–607 (#787).
  2. European Agency for the Evaluation of Medicinal Products. International Conference on Harmonisation-World Health Organization. Guideline for good clinical practice. ICH Harmonised Tripartite Guideline. Good clinical practice. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf (2017). Accessed 6 Feb 2017.

Metadata

Authors
Hausner, H., Derving Karsbøl, J., Holst, A. G., Jacobsen, J. B., Wagner, F.-D., Golor, G., & Anderson, T. W.
Affiliations
Novo Nordisk (Denmark) (DK)
Venue
Clinical Pharmacokinetics
Published
2017-03-27
Volume
56
Issue
11
Pages
1391-1401
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2599180887
Cited by
62
References
32
Citations by year
2026: 8 · 2025: 10 · 2024: 9 · 2023: 2 · 2022: 9 · 2021: 2 · 2020: 5 · 2019: 10 · 2018: 6 · 2017: 1
FWCI
4.59
Type
journal article
Language
en
Open access
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, drug-drug interactions, pharmacokinetics, metformin, warfarin, atorvastatin, digoxin, glucagon-like peptide-1 analogues, type 2 diabetes, anticoagulation, statins, adverse events, dose adjustment
MeSH terms
Atorvastatin, Semaglutide, Adolescent, Adult, Digoxin, Drug Interactions, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Warfarin, Cross-Over Studies, Young Adult, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. https://app.cochat.ai/papers/10.1007/s40262-017-0532-6
The paper
Hausner, H., Derving Karsbøl, J., Holst, A. G., Jacobsen, J. B., Wagner, F.-D., Golor, G., & Anderson, T. W. (2017). Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-017-0532-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.